AARD
AardvarkยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AARD
Aardvark Therapeutics, Inc.
A biopharmaceutical company dedicated to developing drugs for weight loss and metabolic disease treatment
Pharmaceutical
05/17/2017
02/13/2025
NASDAQ Stock Exchange
22
12-31
Common stock
4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122
--
Aardvark Therapeutics, Inc., was incorporated in Delaware on May 17, 2017. The Company is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies to activate innate homeostasis pathways for the treatment of metabolic diseases. The company is targeting biological pathways associated with hunger relief that the company believes have the potential to deliver transformative outcomes for patients. The company has focused its efforts on developing selective compounds, bitter taste receptors for hunger-related conditions.
Company Financials
EPS
AARD has released its 2025 Q3 earnings. EPS was reported at -0.75, versus the expected -0.8, beating expectations. The chart below visualizes how AARD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
